<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11679943</article-id><article-id pub-id-type="doi">10.3390/jcm13247587</article-id><article-id pub-id-type="publisher-id">jcm-13-07587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Management of Hereditary Transthyretin Amyloidosis (ATTRv) Patients and Asymptomatic Carriers in Spain: The EMPATIa Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4834-0843</contrib-id><name><surname>Losada L&#x000f3;pez</surname><given-names>In&#x000e9;s</given-names></name><xref rid="af1-jcm-13-07587" ref-type="aff">1</xref><xref rid="af2-jcm-13-07587" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Gonzalez-Moreno</surname><given-names>Juan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-jcm-13-07587" ref-type="aff">1</xref><xref rid="af2-jcm-13-07587" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Buades Rein&#x000e9;s</surname><given-names>Juan</given-names></name><xref rid="af1-jcm-13-07587" ref-type="aff">1</xref><xref rid="af2-jcm-13-07587" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sevilla</surname><given-names>Teresa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-jcm-13-07587" ref-type="aff">3</xref><xref rid="af4-jcm-13-07587" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Martinez Valle</surname><given-names>Fernando</given-names></name><xref rid="af5-jcm-13-07587" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Gal&#x000e1;n D&#x000e1;vila</surname><given-names>Luc&#x000ed;a</given-names></name><xref rid="af6-jcm-13-07587" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz Beamud</surname><given-names>Francisco</given-names></name><xref rid="af7-jcm-13-07587" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>B&#x000e1;rcena Llona</surname><given-names>Jos&#x000e9; Eulalio</given-names></name><xref rid="af8-jcm-13-07587" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Romero Acebal</surname><given-names>Manuel</given-names></name><xref rid="af9-jcm-13-07587" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Tarilonte</surname><given-names>Patricia</given-names></name><xref rid="af10-jcm-13-07587" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-5081-6469</contrib-id><name><surname>Setaro</surname><given-names>Francesca</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af10-jcm-13-07587" ref-type="aff">10</xref><xref rid="c1-jcm-13-07587" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Sinning</surname><given-names>Christoph</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-13-07587"><label>1</label>Internal Medicine Department, Hospital Universitario Son Ll&#x000e0;tzer, Palma de Mallorca, 07198 Palma, Spain</aff><aff id="af2-jcm-13-07587"><label>2</label>Balearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis, Instituto de Investigaci&#x000f3;n Sanitaria de las Islas Baleares (IdISBa), 07198 Palma, Spain</aff><aff id="af3-jcm-13-07587"><label>3</label>Neurology Department, Hospital Universitari i Polit&#x000e8;cnic La Fe &#x00026; IIS La Fe Universitat de Val&#x000e8;ncia, 46010 Valencia, Spain</aff><aff id="af4-jcm-13-07587"><label>4</label>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Enfermedades Raras (CIBERER), 28034 Madrid, Spain</aff><aff id="af5-jcm-13-07587"><label>5</label>Internal Medicine Department, Hospital Universitario Vall d&#x02019;Hebron, 08035 Barcelona, Spain</aff><aff id="af6-jcm-13-07587"><label>6</label>Neurology Department, Hospital Cl&#x000ed;nico San Carlos, IdISSC, 28040 Madrid, Spain</aff><aff id="af7-jcm-13-07587"><label>7</label>Internal Medicine Department, Hospital Universitario Juan Ram&#x000f3;n Jim&#x000e9;nez, 21005 Huelva, Spain</aff><aff id="af8-jcm-13-07587"><label>8</label>Neurology Department, Hospital Universitario Cruces, 48903 Barakaldo, Spain</aff><aff id="af9-jcm-13-07587"><label>9</label>Neurology Department, Hospital Universitario Virgen de la Victoria, 29010 M&#x000e1;laga, Spain</aff><aff id="af10-jcm-13-07587"><label>10</label>Pfizer S.L.U., 28108 Madrid, Spain</aff><author-notes><corresp id="c1-jcm-13-07587"><label>*</label>Correspondence: <email>francesca.setaro@pfizer.com</email>; Tel.: +34-914909322</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>13</volume><issue>24</issue><elocation-id>7587</elocation-id><history><date date-type="received"><day>11</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>08</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Hereditary transthyretin amyloidosis (ATTRv) is an autosomal-dominant systemic disease, where amyloid fibrils accumulate especially in the peripheral and autonomic nervous systems and in the heart. The aim of the present work was to outline the follow-up and type of management received by asymptomatic carriers (ACs) and <italic toggle="yes">Coutinho</italic> stage 1 ATTRv patients in Spain. <bold>Methods:</bold> A cross-sectional, non-interventional study was conducted throughout seven experienced hospitals in Spain. A total of 86 ACs without neurological symptoms and 19 <italic toggle="yes">Coutinho</italic> stage 1 ATTRv patients diagnosed 12 months before their enrollment were included. Clinical and demographic data, red flags, and neurological and cardiological evaluations were gathered. In addition, site variables were collected from four centers to describe the clinical management of ATTRv. <bold>Results:</bold> ATTRv clinical management varied depending on the center setting but was primarily overseen by neurology and internal medicine, which were responsible for the holistic follow-up of ACs and patients. Routinely, neurologists, neurophysiologists, cardiologists, and internal medicine conducted the follow-up. Specialties involved in initial AC assessment were neurophysiologists and cardiologists in 100% of cases, neurologists (75%), internists and geneticists (50%), and ophthalmologists (25%). A review of the medical tests performed proved an exhaustive management of the study population. Stable patients were followed up every 6 months, while those under evolution were monitored every 3&#x02013;6 months. The frequency of monitoring of ACs was annual, and carriers classified with doubtful disease onset were visited every 3&#x02013;6 months. <bold>Conclusions:</bold> The EMPATIa study provides valuable insights into the management of ATTRv in a real-world clinical setting in highly experienced hospitals in Spain. It demonstrates that multidisciplinary practice and enhanced disease awareness may lead to a reduction in diagnostic delay.</p></abstract><kwd-group><kwd>transthyretin</kwd><kwd>amyloidosis</kwd><kwd>ATTRv mutation</kwd><kwd>management</kwd></kwd-group><funding-group><award-group><funding-source>Pfizer SLU</funding-source></award-group><funding-statement>This study was sponsored by Pfizer SLU.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-13-07587"><title>1. Introduction</title><p>Hereditary transthyretin amyloidosis (ATTRv) is an autosomal-dominant systemic disease with variable penetrance, marked by the deposit of transthyretin (TTR) in several locations of the body. So far, more than 150 distinct genetic mutations have been observed in the <italic toggle="yes">TTR</italic> gene [<xref rid="B1-jcm-13-07587" ref-type="bibr">1</xref>,<xref rid="B2-jcm-13-07587" ref-type="bibr">2</xref>]. The overall prevalence of ATTRv is less than 1 case per 100,000 inhabitants, for what is considered a rare disease, but there are some endemic areas where the prevalence is higher (Portugal, Japan, Sweden, and Brazil) [<xref rid="B3-jcm-13-07587" ref-type="bibr">3</xref>]. Specifically, two high-prevalence (endemic) areas exist in Spain, Mallorca (Balearic Islands) and Valverde del Camino (Huelva) [<xref rid="B4-jcm-13-07587" ref-type="bibr">4</xref>].</p><p>TTR is a mainly liver-synthesized protein that is also produced in the choroid plexus and retinal pigment epithelium. TTR, in tetramer form, is responsible for transporting the thyroid hormone thyroxine (T<sub>4</sub>) and retinol (vitamin A) through the plasma and cerebrospinal fluid. In fact, ATTR is a product of TTR tetramer dissociation. TTR monomers experience conformational changes, producing non-native oligomers and amyloid fibrils [<xref rid="B5-jcm-13-07587" ref-type="bibr">5</xref>]. These amyloid fibrils accumulate in different tissues, particularly targeting the peripheral and autonomic nervous systems and the cardiac muscle [<xref rid="B2-jcm-13-07587" ref-type="bibr">2</xref>], leading to neuropathy and cardiomyopathy [<xref rid="B6-jcm-13-07587" ref-type="bibr">6</xref>], but also in the eyes or kidneys [<xref rid="B7-jcm-13-07587" ref-type="bibr">7</xref>], ultimately leading to a systemic dysfunction [<xref rid="B8-jcm-13-07587" ref-type="bibr">8</xref>].</p><p>The EMPATIa study aimed to describe the characteristics and management of <italic toggle="yes">Coutinho</italic> stage 1 ATTRv patients with polyneuropathy (PN) and asymptomatic carriers (ACs) of a <italic toggle="yes">TTR</italic> gene mutation from endemic and non-endemic areas in Spain. Recently, the clinical profile description of these populations has been published, confirming the multisystemic clinical profile of the disease across Spain [<xref rid="B9-jcm-13-07587" ref-type="bibr">9</xref>]. Here, the mean diagnostic delay was 1.8 years, shorter than the 3&#x02013;4 years reported in earlier studies [<xref rid="B10-jcm-13-07587" ref-type="bibr">10</xref>,<xref rid="B11-jcm-13-07587" ref-type="bibr">11</xref>].</p><p>Diagnosis remains a challenge due to the lack of distinctive symptoms and the incomplete penetrance of the disease, with late diagnosis directly impacting the early initiation of therapies and prognosis [<xref rid="B7-jcm-13-07587" ref-type="bibr">7</xref>]. A systemic approach and multidisciplinary evaluation may enable an early diagnosis by means of the identification of initial clinical manifestations, also known as &#x0201c;red flags&#x0201d; [<xref rid="B7-jcm-13-07587" ref-type="bibr">7</xref>,<xref rid="B12-jcm-13-07587" ref-type="bibr">12</xref>,<xref rid="B13-jcm-13-07587" ref-type="bibr">13</xref>]. In this regard, the present study outlines the follow-up and management approaches provided to <italic toggle="yes">TTR</italic> gene mutation ACs and <italic toggle="yes">Coutinho</italic> stage 1 ATTRv-PN patients within the EMPATIa study.</p></sec><sec id="sec2-jcm-13-07587"><title>2. Materials and Methods</title><sec id="sec2dot1-jcm-13-07587"><title>2.1. Study Population</title><p>Eligibility criteria for the EMPATIa study have previously been described [<xref rid="B9-jcm-13-07587" ref-type="bibr">9</xref>]. Briefly, this study included ACs without PN symptoms related to ATTRv and <italic toggle="yes">Coutinho</italic> stage 1 ATTRv-PN patients diagnosed in the 12 months prior to the recruitment. Exclusion criteria included individuals with diabetes mellitus, <italic toggle="yes">Coutinho</italic> stage 2/3 ATTRv, monoclonal gammopathy of undetermined significance, pregnant or breastfeeding woman, and those who did not provide informed consent.</p></sec><sec id="sec2dot2-jcm-13-07587"><title>2.2. Study Design</title><p>EMPATIa is a multicenter, cross-sectional, non-interventional, descriptive epidemiological study carried out at seven experienced hospitals from endemic (Huelva and Mallorca) and non-endemic areas (Madrid, Barcelona, Vizcaya, M&#x000e1;laga, and Valencia) in Spain. The conception and validation of the study protocol were performed before the last publication of guidelines [<xref rid="B14-jcm-13-07587" ref-type="bibr">14</xref>], meaning that the established criterion for discriminating between ACs and patients was based on the presence of PN, mostly diagnosed on the basis of large fiber involvement by electromyogram. However, by clinical decision, 3 subjects presenting autonomic dysfunction without sensory-motor PN were also classified as patients [<xref rid="B9-jcm-13-07587" ref-type="bibr">9</xref>]. This trial was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Clinical Research Ethics Committee of Vall d&#x02019;Hebron Hospital (Barcelona). All patients provided written informed consent.</p></sec><sec id="sec2dot3-jcm-13-07587"><title>2.3. Clinical Management</title><p>Although seven centers participated in the EMPATIa study, only four centers included data on ACs and patient management during the study period. In order to describe the clinical management and organizational setting of centers, the following variables were collected for each participating site: total number of ACs monitored in the center and maximum time and frequency of follow-up, specialists involved in baseline and follow-up visits, tests performed, and scales employed at diagnosis and/or follow-up for both ACs and ATTRv patients.</p><p>The following assessments were compiled: (i) sensory-motor and autonomic neurological impairment using electromyography (EMG); (ii) study of autonomic nervous system by scales (COMPASS 31); (iii) cardiovascular autonomic dysfunction by the use of the Tilt test and the RR interval; (iv) sudomotor function and electrochemical skin conductance (ESC) on the SUDOSCAN device (Impetomedical, Issy-les-Moulineaux, France); (v) the ATTRv-related neurological status determined by the neuropathy impairment score (NIS); (vi) the quality of life (QoL) by using the scale of the Norfolk Quality of Life Questionnaire for Diabetic Neuropathy (Norfolk QoL-DN); (vii) comorbidities by means of Charlson comorbidity index (CCI); (viii) cardiological study by the use of electrocardiogram (ECG) and echocardiogram (ECHO); and (iv) laboratory data, including serum biomarkers such as the N-terminal prohormone of brain natriuretic peptide (NT-proBNP), troponin T and I, albumin and transthyretin levels, and evidence of microalbuminuria and proteinuria.</p></sec><sec id="sec2dot4-jcm-13-07587"><title>2.4. ATTRv Amyloidosis Red Flags</title><p>All data collected were obtained from electronic medical records and recorded in an electronic case report form (eCRF). As previously described, ATTRv red flags were collected and categorized as follows: autonomic and peripheral sensory-motor neuropathies; central nervous system (CNS) manifestations; ocular, kidney, gastrointestinal, and cardiac alterations; and carpal tunnel syndrome [<xref rid="B9-jcm-13-07587" ref-type="bibr">9</xref>,<xref rid="B12-jcm-13-07587" ref-type="bibr">12</xref>]. Autonomic neuropathy is defined as orthostatic hypotension, recurrent urinary tract infections due to urinary retention, sexual dysfunction, and sweating disturbances. All AC red flags recorded in the eCRD from the seven centers included in this study were analyzed to identify potential differences based on the frequency of follow-up.</p></sec><sec id="sec2dot5-jcm-13-07587"><title>2.5. Statistical Analysis</title><p>A descriptive statistical analysis was conducted for all variables, including measures of central tendency and dispersion for continuous variables (median and interquartile range [IQR] or mean and standard deviation [SD]) and absolute and relative frequencies for categorical variables. Student&#x02019;s <italic toggle="yes">t</italic>-test and the Mann&#x02013;Whitney U test were used to compare quantitative variables, and Chi-square (&#x003c7;2) or Fisher tests for qualitative variables. Tests were two-tailed with a significance level of 5%.</p></sec></sec><sec sec-type="results" id="sec3-jcm-13-07587"><title>3. Results</title><sec id="sec3dot1-jcm-13-07587"><title>3.1. Clinical Management of Hereditary Transthyretin Amyloidosis</title><p>At the time of this study, 138 ACs were under follow-up in the study centers. The mean number of ACs followed up in the four included centers was 34.5 (range 15&#x02013;84), 46.1% were male; the age of ACs ranged between 19 and 81 years old, and the mean age at <italic toggle="yes">TTR</italic> gene mutation identification was 42.9 years old (range 41&#x02013;45).</p><p>Regarding mutations, 100% of the sites followed up carriers with V50M; 75% of sites, carriers with S97Y mutation; and 50% of the centers, mutations V142I and E109K. Other mutations reported were T60A, D38E, and T68I. Initial AC evaluation was carried out by neurophysiologists and cardiologists (all centers), neurologists (75% of centers), internist physicians and geneticists (half of the centers), and ophthalmologists (25% of centers), while the routine follow-up monitoring was primarily driven by specialists in neurophysiology, neurology, and cardiology (75%) and internist physicians (50%) (<xref rid="jcm-13-07587-f001" ref-type="fig">Figure 1</xref>).</p><p>Interestingly, a careful review of the medical tests and scales used for the initial evaluation and follow-up demonstrated an exhaustive and integrative management of the study population (<xref rid="jcm-13-07587-f002" ref-type="fig">Figure 2</xref>). The initial AC visit was the most complete, and all centers included ECG, ECHO, EMG, NIS, Norfolk-QoL-DN, CCI, and RR interval; the COMPASSS-31 scale was used in 50% of centers. In the successive medical examinations, ECG, NIS, and Norfolk-QoL-DN were performed by all centers, and RR interval was used in 75% of centers, while ECHO, EMG, and COMPASS-31 were routinely performed in 50% of centers among other available tests. The frequency of monitoring was annual, and in the case of a carrier classified with doubtful disease onset, the frequency of visits was every 3&#x02013;6 months.</p><p>With respect to patients&#x02019; initial assessment, all centers performed ECG; 75% included ECHO, EMG, NIS, Norfolk QoL-DN, CCI, and RR interval; and 50% included COMPASS-31. At follow-up, the same tests and scales were used in the same percentages in all centers as in the first patient visit, except for the Tilt test (<xref rid="jcm-13-07587-f002" ref-type="fig">Figure 2</xref>). The frequency of follow-up was every 6 months for stable patients and every 3&#x02013;6 months for patients under evolution (unstable).</p></sec><sec id="sec3dot2-jcm-13-07587"><title>3.2. ACs Characteristics According to Follow-Up Frequency</title><p>In order to determine whether there were different/specific characteristics among included ACs (n = 86) who require more or less follow-up, a cut-off of 12 months was applied. As mentioned above, annual monitoring was the predominant type of follow-up inside this population (n = 56 [71.8%]; follow-up frequency every 3 [n = 1], 6 [n = 20], 9 months [n = 1]). We found non-statistical differences in the AC age subgroups, with the subgroup monitored with a lower frequency being younger (43.6 &#x000b1; 15.1 years) than ACs more frequently monitored (49.3 &#x000b1; 11.8 years; 0 = 0.074). Within the group of subjects followed up yearly, 85.7% (n = 48) were V50M, 10.7% (n = 6) were S97Y, and only 1.8% (n = 1) were V142I or T60A. The group monitored with a frequency &#x0003c; 1 annual visit was significantly enriched in V142I mutation (1.8 % vs 27.3%; <italic toggle="yes">p</italic> = 0.006); 50% (n = 11) of subjects were V50M, 13.6% (n = 3) were S97Y, and 9.1% (n = 2) were D38E. No significant differences were found in anamnesis or red flags between carrier subgroups (<xref rid="jcm-13-07587-t001" ref-type="table">Table 1</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-jcm-13-07587"><title>4. Discussion</title><p>The EMPATIa study focused on the characterization of <italic toggle="yes">TTR</italic> gene mutation ACs and <italic toggle="yes">Coutinho</italic> stage 1 ATTRv patients in order to evaluate the early stages of the disease and to gain further insight into the management that these patients receive in a real-world clinical practice scenario where healthcare professionals have extensive experience with this disease. In this regard, an analysis of the multidisciplinary assessment and follow-up performed in both ACs and ATTR-PN patients was carried out.</p><p>The time to reach a diagnosis in ATTRv varies substantially between endemic (1 year) and non-endemic areas (3&#x02013;4 years), and disease awareness plays a crucial role in reducing diagnostic delays [<xref rid="B11-jcm-13-07587" ref-type="bibr">11</xref>]. In fact, different studies showed a high number of visits to hospital services of ATTRv patients during the 3 years prior to diagnosis as well as an important deterioration in their QoL during the same period [<xref rid="B15-jcm-13-07587" ref-type="bibr">15</xref>,<xref rid="B16-jcm-13-07587" ref-type="bibr">16</xref>]. The EMPATIa study showed that the overall diagnostic delay reported across experienced centers in Spain was 1.8 years, confirming again that a high level of knowledge on ATTRv allows the identification of patients in early stages [<xref rid="B9-jcm-13-07587" ref-type="bibr">9</xref>]. A coordinated and systematic follow-up of ACs, involving multiple disciplines, is crucial for the early detection of symptoms, facilitating timely treatment and delaying disease progression [<xref rid="B7-jcm-13-07587" ref-type="bibr">7</xref>,<xref rid="B17-jcm-13-07587" ref-type="bibr">17</xref>,<xref rid="B18-jcm-13-07587" ref-type="bibr">18</xref>], a recommendation that is also met in the clinical practice of the Spanish centers analyzed. Moreover, AC education is essential to guarantee their collaboration in the early identification of the first disease signs and symptoms that appear [<xref rid="B7-jcm-13-07587" ref-type="bibr">7</xref>].</p><p>Since symptomatic ATTRv is associated with an increased morbidity and mortality, and induces a substantial impairment in patients&#x02019; QoL, it is vital to perform a proper follow-up adapted to the course and severity of the disease and therefore the response to the treatment. Clinical guidelines recommend that patients be monitored every 6&#x02013;12 months [<xref rid="B19-jcm-13-07587" ref-type="bibr">19</xref>]. In the centers participating in this study, we have confirmed that ATTRv management was carried out according to international guidelines [<xref rid="B19-jcm-13-07587" ref-type="bibr">19</xref>]. Indeed, a comparative analysis with international standards revealed that the Spanish centers analyzed applied an intensified follow-up since stable patients were commonly monitored by a specialist every 6 months, while patients under evolution were monitored every 3&#x02013;6 months, independently of whether care was provided in endemic or non-endemic areas [<xref rid="B17-jcm-13-07587" ref-type="bibr">17</xref>,<xref rid="B19-jcm-13-07587" ref-type="bibr">19</xref>]. In addition, ACs monitored more frequently than yearly were slightly older than ACs monitored every 12 months, probably because their predicted age of onset of symptomatic disease was approaching. We could also speculate that the shorter time to diagnosis described in these centers [<xref rid="B9-jcm-13-07587" ref-type="bibr">9</xref>] might be attributed to more frequent follow-up. The EMPATIa results highlighted the importance of adapting the follow-up schedule case by case, according to mutation and familiar clinical history.</p><p>Follow-up testing and assessments for ACs should be tailored to the expected phenotypic presentation associated with each specific mutation. In terms of recommended clinical tools for the management of identified ACs [<xref rid="B7-jcm-13-07587" ref-type="bibr">7</xref>], the EMPATIa study showed alignment with recommended techniques to identify potentially earlier signs of the disease, incorporating follow-up questionnaires for sensorimotor and autonomic symptoms, neurological examination, neurophysiological evaluations, autonomic functional testing, and relevant cardiac investigations.</p><p>Disease progression has effects at the systemic level and in several domains, such as functional capacity, QoL, levels of laboratory biomarkers, etc., the interpretation of which requires multidisciplinary expertise [<xref rid="B20-jcm-13-07587" ref-type="bibr">20</xref>]. Therefore, healthcare professionals need a trustworthy regular assessment to identify early signals of disease appearance and to assess disease evolution in order to make suitable therapeutic decisions on an individual basis [<xref rid="B18-jcm-13-07587" ref-type="bibr">18</xref>]. In EMPATIa-participating hospitals, ATTRv was overseen and referred by a single professional (neurologist or internist). However, the study results highlighted that initial assessment and follow-up visits were conducted by different specialties, ensuring holistic care of both populations, with follow-up varying slightly between centers due to the casuistry of each hospital. A timely and precise diagnosis provides patients with prolonged life expectancy, prevents hospitalizations, and saves costs for the national health system [<xref rid="B21-jcm-13-07587" ref-type="bibr">21</xref>].</p></sec><sec sec-type="conclusions" id="sec5-jcm-13-07587"><title>5. Conclusions</title><p>The EMPATIa study described accurately a representative population of ACs and <italic toggle="yes">Coutinho</italic> stage 1 ATTRv-PN patients with early stages of neurological impairment diagnosed in the last 12 months in seven Spanish hospitals, offering an overview of ATTRv management in a real-world clinical practice setting. The results confirmed that extensive disease awareness and integrated multidisciplinary management of ACs and patients based on a systematic approach and tailored to each clinical case is crucial for the early detection of the disease and therefore for improving patient care. We hope that this knowledge may contribute to the improvement of AC/ATTRv patient handling and guide clinicians in making suitable therapeutic decisions.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank Miriam Ejarque (Medical Statistics Consulting SL) for medical writing services and editorial assistance and Pfizer for providing us with this service. The authors would like to thank Laura Bernal (Pfizer SLU) for scientific support for the manuscript. The authors would like to thank the following investigators who participated in this study: Eugenia Cisneros-Barroso, Juan Carlos Gomez-Esteban, Marina Frasquet Carrera, Amaia Jauregui Barrutia, Cristina Borrachero Garro.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>All authors were involved in the conception of this study. F.S. wrote the initial draft. I.L.L., J.G.-M., J.B.R., T.S., F.M.V., L.G.D., F.M.B., J.E.B.L., M.R.A., P.T., and F.S. made significant contributions to the original draft and to the final manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Clinical Research Ethics Committee of Vall d&#x02019;Hebron Hospital (Barcelona) on 19 October 2017 (Protocol study code B3461063).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets used during the current study are not openly available due to reasons of sensitivity and are available from the corresponding author on reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>I.L.L. has received fees as a scientific advisor or participant in clinical studies from (in alphabetical order) Alnylam, Akcea, and Pfizer. J.G.-M. has received fees as a scientific advisor or participant in clinical studies from (in alphabetical order) Alnylam, Akcea, and Pfizer. J.B.R. has no conflicts of interest to declare. T.S. has received fees as a scientific advisor or participant in clinical studies from (in alphabetical order) Alnylam, Akcea, and Pfizer. F.M.V. has received fees as a scientific advisor or participant in clinical studies from (in alphabetical order) Alnylam, Akcea, and Pfizer. L.G.D. has received fees as a scientific advisor or participant in clinical studies from (in alphabetical order) Akcea, Alnylam, Astrazeneca, Pfizer, and Sobi. F.M.B. has received fees as a scientific advisor or participant in clinical studies from (in alphabetical order) Akcea, Alnylam, Pfizer, and Sobi. J.E.B.L. has no conflicts of interest to declare. M.R.A. has received fees as a scientific advisor or participant in clinical studies from (in alphabetical order) Alnylam and Pfizer. P.T. is a full-time employee of Pfizer SLU and holds stock and stock options in Pfizer Inc. F.S. is a full-time employee of Pfizer SLU and holds stock and stock options in Pfizer Inc.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AC</td><td align="left" valign="middle" rowspan="1" colspan="1">asymptomatic carrier</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATTR</td><td align="left" valign="middle" rowspan="1" colspan="1">transthyretin amyloidosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATTRv</td><td align="left" valign="middle" rowspan="1" colspan="1">hereditary transthyretin amyloidosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EMPATIa</td><td align="left" valign="middle" rowspan="1" colspan="1">Carrier Management Study in Transthyretin hereditary Amyloidosis (from the Spanish: &#x0201c;Estudio sobre el Manejo de los Portadores en Amiloidosis hereditaria por Transtiretina&#x0201d;)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ESC</td><td align="left" valign="middle" rowspan="1" colspan="1">electrochemical skin conductance </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECG</td><td align="left" valign="middle" rowspan="1" colspan="1">electrocardiogram</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECHO</td><td align="left" valign="middle" rowspan="1" colspan="1">echocardiogram </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NORFOLK QoL-DN</td><td align="left" valign="middle" rowspan="1" colspan="1">Norfolk quality of life questionnaire for diabetic neuropathy </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NIS</td><td align="left" valign="middle" rowspan="1" colspan="1">neuropathy impairment score</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NT-proBNP</td><td align="left" valign="middle" rowspan="1" colspan="1">N-terminal prohormone of brain natriuretic peptide </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QoL</td><td align="left" valign="middle" rowspan="1" colspan="1">quality of life</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PN</td><td align="left" valign="middle" rowspan="1" colspan="1">polyneuropathy </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TTR</td><td align="left" valign="middle" rowspan="1" colspan="1">transthyretin</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-jcm-13-07587"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ueda</surname><given-names>M.</given-names></name>
</person-group><article-title>Transthyretin: Its function and amyloid formation</article-title><source>Neurochem. Int.</source><year>2022</year><volume>155</volume><fpage>105313</fpage><pub-id pub-id-type="doi">10.1016/j.neuint.2022.105313</pub-id><pub-id pub-id-type="pmid">35218869</pub-id>
</element-citation></ref><ref id="B2-jcm-13-07587"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nativi-Nicolau</surname><given-names>J.N.</given-names></name>
<name><surname>Karam</surname><given-names>C.</given-names></name>
<name><surname>Khella</surname><given-names>S.</given-names></name>
<name><surname>Maurer</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Screening for ATTR amyloidosis in the clinic: Overlapping disorders, misdiagnosis, and multiorgan awareness</article-title><source>Heart Fail. Rev.</source><year>2022</year><volume>27</volume><fpage>785</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1007/s10741-021-10080-2</pub-id><pub-id pub-id-type="pmid">33609196</pub-id>
</element-citation></ref><ref id="B3-jcm-13-07587"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Condoluci</surname><given-names>A.</given-names></name>
<name><surname>Theaudin</surname><given-names>M.</given-names></name>
<name><surname>Schwotzer</surname><given-names>R.</given-names></name>
<name><surname>Pazhenkottil</surname><given-names>A.P.</given-names></name>
<name><surname>Arosio</surname><given-names>P.</given-names></name>
<name><surname>Averaimo</surname><given-names>M.</given-names></name>
<name><surname>Bacher</surname><given-names>U.</given-names></name>
<name><surname>Bode</surname><given-names>P.</given-names></name>
<name><surname>Cavalli</surname><given-names>A.</given-names></name>
<name><surname>Dirnhofer</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Management of transthyretin amyloidosis</article-title><source>Swiss Med. Wkly.</source><year>2021</year><volume>151</volume><fpage>w30053</fpage><pub-id pub-id-type="doi">10.4414/SMW.2021.w30053</pub-id><pub-id pub-id-type="pmid">34694105</pub-id>
</element-citation></ref><ref id="B4-jcm-13-07587"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia-Pavia</surname><given-names>P.</given-names></name>
<name><surname>Dominguez</surname><given-names>F.</given-names></name>
<name><surname>Gonzalez-Lopez</surname><given-names>E.</given-names></name>
</person-group><article-title>Transthyretin amyloid cardiomyopathy</article-title><source>Med. Clin.</source><year>2021</year><volume>156</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.medcli.2020.06.064</pub-id></element-citation></ref><ref id="B5-jcm-13-07587"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yee</surname><given-names>A.W.</given-names></name>
<name><surname>Aldeghi</surname><given-names>M.</given-names></name>
<name><surname>Blakeley</surname><given-names>M.P.</given-names></name>
<name><surname>Ostermann</surname><given-names>A.</given-names></name>
<name><surname>Mas</surname><given-names>P.J.</given-names></name>
<name><surname>Moulin</surname><given-names>M.</given-names></name>
<name><surname>de Sanctis</surname><given-names>D.</given-names></name>
<name><surname>Bowler</surname><given-names>M.W.</given-names></name>
<name><surname>Mueller-Dieckmann</surname><given-names>C.</given-names></name>
<name><surname>Mitchell</surname><given-names>E.P.</given-names></name>
<etal/>
</person-group><article-title>A molecular mechanism for transthyretin amyloidogenesis</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>925</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-08609-z</pub-id><pub-id pub-id-type="pmid">30804345</pub-id>
</element-citation></ref><ref id="B6-jcm-13-07587"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dispenzieri</surname><given-names>A.</given-names></name>
<name><surname>Coelho</surname><given-names>T.</given-names></name>
<name><surname>Conceicao</surname><given-names>I.</given-names></name>
<name><surname>Waddington-Cruz</surname><given-names>M.</given-names></name>
<name><surname>Wixner</surname><given-names>J.</given-names></name>
<name><surname>Kristen</surname><given-names>A.V.</given-names></name>
<name><surname>Rapezzi</surname><given-names>C.</given-names></name>
<name><surname>Plante-Bordeneuve</surname><given-names>V.</given-names></name>
<name><surname>Gonzalez-Moreno</surname><given-names>J.</given-names></name>
<name><surname>Maurer</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update</article-title><source>Orphanet. J. Rare Dis.</source><year>2022</year><volume>17</volume><fpage>236</fpage><pub-id pub-id-type="doi">10.1186/s13023-022-02359-w</pub-id><pub-id pub-id-type="pmid">35717381</pub-id>
</element-citation></ref><ref id="B7-jcm-13-07587"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Concei&#x000e7;&#x000e3;o</surname><given-names>I.</given-names></name>
<name><surname>Damy</surname><given-names>T.</given-names></name>
<name><surname>Romero</surname><given-names>M.</given-names></name>
<name><surname>Gal&#x000e1;n</surname><given-names>L.</given-names></name>
<name><surname>Attarian</surname><given-names>S.</given-names></name>
<name><surname>Luigetti</surname><given-names>M.</given-names></name>
<name><surname>Sadeh</surname><given-names>M.</given-names></name>
<name><surname>Sarafov</surname><given-names>S.</given-names></name>
<name><surname>Tournev</surname><given-names>I.</given-names></name>
<name><surname>Ueda</surname><given-names>M.</given-names></name>
</person-group><article-title>Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations</article-title><source>Amyloid</source><year>2019</year><volume>26</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/13506129.2018.1556156</pub-id><pub-id pub-id-type="pmid">30793974</pub-id>
</element-citation></ref><ref id="B8-jcm-13-07587"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibrahim</surname><given-names>R.B.</given-names></name>
<name><surname>Liu</surname><given-names>Y.T.</given-names></name>
<name><surname>Yeh</surname><given-names>S.Y.</given-names></name>
<name><surname>Tsai</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin Amyloidosis</article-title><source>Front. Physiol.</source><year>2019</year><volume>10</volume><elocation-id>338</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2019.00338</pub-id><pub-id pub-id-type="pmid">31001136</pub-id>
</element-citation></ref><ref id="B9-jcm-13-07587"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galan Davila</surname><given-names>L.</given-names></name>
<name><surname>Martinez Valle</surname><given-names>F.</given-names></name>
<name><surname>Buades Reines</surname><given-names>J.</given-names></name>
<name><surname>Gonzalez-Moreno</surname><given-names>J.</given-names></name>
<name><surname>Losada Lopez</surname><given-names>I.</given-names></name>
<name><surname>Sevilla</surname><given-names>T.</given-names></name>
<name><surname>Munoz Beamud</surname><given-names>F.</given-names></name>
<name><surname>Barcena Llona</surname><given-names>J.E.</given-names></name>
<name><surname>Romero Acebal</surname><given-names>M.</given-names></name>
<name><surname>Setaro</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>A description of variant transthyretin amyloidosis (ATTRv) stage 1 patients and asymptomatic carriers in Spain: The EMPATIa study</article-title><source>Orphanet. J. Rare Dis.</source><year>2024</year><volume>19</volume><fpage>323</fpage><pub-id pub-id-type="doi">10.1186/s13023-024-03304-9</pub-id><pub-id pub-id-type="pmid">39242501</pub-id>
</element-citation></ref><ref id="B10-jcm-13-07587"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>D.</given-names></name>
<name><surname>Ando</surname><given-names>Y.</given-names></name>
<name><surname>Beir&#x000e3;o</surname><given-names>J.M.</given-names></name>
<name><surname>Coelho</surname><given-names>T.</given-names></name>
<name><surname>Gertz</surname><given-names>M.A.</given-names></name>
<name><surname>Gillmore</surname><given-names>J.D.</given-names></name>
<name><surname>Hawkins</surname><given-names>P.N.</given-names></name>
<name><surname>Lousada</surname><given-names>I.</given-names></name>
<name><surname>Suhr</surname><given-names>O.B.</given-names></name>
<name><surname>Merlini</surname><given-names>G.</given-names></name>
</person-group><article-title>Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy</article-title><source>J. Neurol.</source><year>2021</year><volume>268</volume><fpage>2109</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09688-0</pub-id><pub-id pub-id-type="pmid">31907599</pub-id>
</element-citation></ref><ref id="B11-jcm-13-07587"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>D.</given-names></name>
<name><surname>Koike</surname><given-names>H.</given-names></name>
<name><surname>Slama</surname><given-names>M.</given-names></name>
<name><surname>Coelho</surname><given-names>T.</given-names></name>
</person-group><article-title>Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease</article-title><source>Nat. Rev. Neurol.</source><year>2019</year><volume>15</volume><fpage>387</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0210-4</pub-id><pub-id pub-id-type="pmid">31209302</pub-id>
</element-citation></ref><ref id="B12-jcm-13-07587"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Concei&#x000e7;&#x000e3;o</surname><given-names>I.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Duarte</surname><given-names>A.</given-names></name>
<name><surname>Obici</surname><given-names>L.</given-names></name>
<name><surname>Schmidt</surname><given-names>H.H.J.</given-names></name>
<name><surname>Simoneau</surname><given-names>D.</given-names></name>
<name><surname>Ong</surname><given-names>M.-L.</given-names></name>
<name><surname>Amass</surname><given-names>L.</given-names></name>
</person-group><article-title>&#x0201c;Red-flag&#x0201d; symptom clusters in transthyretin familial amyloid polyneuropathy</article-title><source>J. Peripher. Nerv. Syst.</source><year>2016</year><volume>21</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/jns.12153</pub-id><pub-id pub-id-type="pmid">26663427</pub-id>
</element-citation></ref><ref id="B13-jcm-13-07587"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Losada</surname><given-names>I.</given-names></name>
<name><surname>Gonzalez-Moreno</surname><given-names>J.</given-names></name>
<name><surname>Rodriguez</surname><given-names>A.</given-names></name>
<name><surname>Uson</surname><given-names>M.</given-names></name>
<name><surname>Ripoll-Vera</surname><given-names>T.</given-names></name>
<name><surname>Ferrer-Nadal</surname><given-names>A.</given-names></name>
<name><surname>Rigo</surname><given-names>E.</given-names></name>
<name><surname>Andreu</surname><given-names>H.</given-names></name>
<name><surname>Figuerola</surname><given-names>A.</given-names></name>
<name><surname>Montala</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>Multidisciplinary approach in the management of hATTR</article-title><source>Eur. J. Clin. Investig.</source><year>2020</year><volume>50</volume><fpage>e13296</fpage><pub-id pub-id-type="doi">10.1111/eci.13296</pub-id><pub-id pub-id-type="pmid">32474919</pub-id>
</element-citation></ref><ref id="B14-jcm-13-07587"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maurer</surname><given-names>M.S.</given-names></name>
<name><surname>Bokhari</surname><given-names>S.</given-names></name>
<name><surname>Damy</surname><given-names>T.</given-names></name>
<name><surname>Dorbala</surname><given-names>S.</given-names></name>
<name><surname>Drachman</surname><given-names>B.M.</given-names></name>
<name><surname>Fontana</surname><given-names>M.</given-names></name>
<name><surname>Grogan</surname><given-names>M.</given-names></name>
<name><surname>Kristen</surname><given-names>A.V.</given-names></name>
<name><surname>Lousada</surname><given-names>I.</given-names></name>
<name><surname>Nativi-Nicolau</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis</article-title><source>Circ. Heart Fail.</source><year>2019</year><volume>12</volume><fpage>e006075</fpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.119.006075</pub-id><pub-id pub-id-type="pmid">31480867</pub-id>
</element-citation></ref><ref id="B15-jcm-13-07587"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lane</surname><given-names>T.</given-names></name>
<name><surname>Fontana</surname><given-names>M.</given-names></name>
<name><surname>Martinez-Naharro</surname><given-names>A.</given-names></name>
<name><surname>Quarta</surname><given-names>C.C.</given-names></name>
<name><surname>Whelan</surname><given-names>C.J.</given-names></name>
<name><surname>Petrie</surname><given-names>A.</given-names></name>
<name><surname>Rowczenio</surname><given-names>D.M.</given-names></name>
<name><surname>Gilbertson</surname><given-names>J.A.</given-names></name>
<name><surname>Hutt</surname><given-names>D.F.</given-names></name>
<name><surname>Rezk</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis</article-title><source>Circulation</source><year>2019</year><volume>140</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.038169</pub-id><pub-id pub-id-type="pmid">31109193</pub-id>
</element-citation></ref><ref id="B16-jcm-13-07587"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000f3;pez-Sainz</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>Hernandez-Hernandez</surname><given-names>A.</given-names></name>
<name><surname>Gonzalez-Lopez</surname><given-names>E.</given-names></name>
<name><surname>Dom&#x000ed;nguez</surname><given-names>F.</given-names></name>
<name><surname>Restrepo-Cordoba</surname><given-names>M.A.</given-names></name>
<name><surname>Cobo-Marcos</surname><given-names>M.</given-names></name>
<name><surname>G&#x000f3;mez-Bueno</surname><given-names>M.</given-names></name>
<name><surname>Hernandez-Perez</surname><given-names>F.J.</given-names></name>
<name><surname>Oteo</surname><given-names>J.F.</given-names></name>
<name><surname>Mirelis</surname><given-names>J.G.</given-names></name>
<etal/>
</person-group><article-title>Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center</article-title><source>Rev. Esp. Cardiol. (Engl. Ed.)</source><year>2021</year><volume>74</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.recesp.2019.12.017</pub-id><pub-id pub-id-type="pmid">32317158</pub-id>
</element-citation></ref><ref id="B17-jcm-13-07587"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>D.</given-names></name>
<name><surname>Suhr</surname><given-names>O.B.</given-names></name>
<name><surname>Hund</surname><given-names>E.</given-names></name>
<name><surname>Obici</surname><given-names>L.</given-names></name>
<name><surname>Tournev</surname><given-names>I.</given-names></name>
<name><surname>Campistol</surname><given-names>J.M.</given-names></name>
<name><surname>Slama</surname><given-names>M.S.</given-names></name>
<name><surname>Hazenberg</surname><given-names>B.P.</given-names></name>
<name><surname>Coelho</surname><given-names>T.</given-names></name>
<name><surname>European Network for</surname><given-names>T.-F.</given-names></name>
</person-group><article-title>First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy</article-title><source>Curr. Opin. Neurol.</source><year>2016</year><volume>29</volume><issue>(Suppl. S1)</issue><fpage>S14</fpage><lpage>S26</lpage><pub-id pub-id-type="doi">10.1097/WCO.0000000000000289</pub-id><pub-id pub-id-type="pmid">26734952</pub-id>
</element-citation></ref><ref id="B18-jcm-13-07587"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Concei&#x000e7;&#x000e3;o</surname><given-names>I.</given-names></name>
<name><surname>Coelho</surname><given-names>T.</given-names></name>
<name><surname>Rapezzi</surname><given-names>C.</given-names></name>
<name><surname>Parman</surname><given-names>Y.</given-names></name>
<name><surname>Obici</surname><given-names>L.</given-names></name>
<name><surname>Gal&#x000e1;n</surname><given-names>L.</given-names></name>
<name><surname>Rousseau</surname><given-names>A.</given-names></name>
</person-group><article-title>Assessment of patients with hereditary transthyretin amyloidosis&#x02014;Understanding the impact of management and disease progression</article-title><source>Amyloid</source><year>2019</year><volume>26</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1080/13506129.2019.1627312</pub-id></element-citation></ref><ref id="B19-jcm-13-07587"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ando</surname><given-names>Y.</given-names></name>
<name><surname>Adams</surname><given-names>D.</given-names></name>
<name><surname>Benson</surname><given-names>M.D.</given-names></name>
<name><surname>Berk</surname><given-names>J.L.</given-names></name>
<name><surname>Plante-Bordeneuve</surname><given-names>V.</given-names></name>
<name><surname>Coelho</surname><given-names>T.</given-names></name>
<name><surname>Conceicao</surname><given-names>I.</given-names></name>
<name><surname>Ericzon</surname><given-names>B.G.</given-names></name>
<name><surname>Obici</surname><given-names>L.</given-names></name>
<name><surname>Rapezzi</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis</article-title><source>Amyloid</source><year>2022</year><volume>29</volume><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1080/13506129.2022.2052838</pub-id><pub-id pub-id-type="pmid">35652823</pub-id>
</element-citation></ref><ref id="B20-jcm-13-07587"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia-Pavia</surname><given-names>P.</given-names></name>
<name><surname>Bengel</surname><given-names>F.</given-names></name>
<name><surname>Brito</surname><given-names>D.</given-names></name>
<name><surname>Damy</surname><given-names>T.</given-names></name>
<name><surname>Duca</surname><given-names>F.</given-names></name>
<name><surname>Dorbala</surname><given-names>S.</given-names></name>
<name><surname>Nativi-Nicolau</surname><given-names>J.</given-names></name>
<name><surname>Obici</surname><given-names>L.</given-names></name>
<name><surname>Rapezzi</surname><given-names>C.</given-names></name>
<name><surname>Sekijima</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy</article-title><source>Eur. J. Heart Fail.</source><year>2021</year><volume>23</volume><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1002/ejhf.2198</pub-id><pub-id pub-id-type="pmid">33915002</pub-id>
</element-citation></ref><ref id="B21-jcm-13-07587"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Formiga</surname><given-names>F.</given-names></name>
<name><surname>Garcia-Pavia</surname><given-names>P.</given-names></name>
<name><surname>Martin Sanchez</surname><given-names>F.J.</given-names></name>
<name><surname>Navarro-Ruiz</surname><given-names>A.</given-names></name>
<name><surname>Rubio-Terres</surname><given-names>C.</given-names></name>
<name><surname>Peral</surname><given-names>C.</given-names></name>
<name><surname>Tarilonte</surname><given-names>P.</given-names></name>
<name><surname>Lopez-Ibanez de Aldecoa</surname><given-names>A.</given-names></name>
<name><surname>Rubio-Rodriguez</surname><given-names>D.</given-names></name>
</person-group><article-title>Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain</article-title><source>Expert Rev. Pharmacoecon Outcomes Res.</source><year>2021</year><volume>21</volume><fpage>1127</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1080/14737167.2021.1933948</pub-id><pub-id pub-id-type="pmid">34047214</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-13-07587-f001"><label>Figure 1</label><caption><p>Specialists involved in initial assessment and routine follow-up of asymptomatic carriers (ACs).</p></caption><graphic xlink:href="jcm-13-07587-g001" position="float"/></fig><fig position="float" id="jcm-13-07587-f002"><label>Figure 2</label><caption><p>Frequency of use of clinical tools for the first assessments and in the follow-up of patients and asymptomatic carriers. AC: asymptomatic carrier; ECG: electrocardiogram; ECHO: echocardiogram; EMG: electromyography; NIS: neuropathy impairment score; CCI: Charlson comorbidity index; Norfolk QoL-DN: Norfolk Quality of Life Questionnaire for Diabetic Neuropathy.</p></caption><graphic xlink:href="jcm-13-07587-g002" position="float"/></fig><table-wrap position="float" id="jcm-13-07587-t001"><object-id pub-id-type="pii">jcm-13-07587-t001_Table 1</object-id><label>Table 1</label><caption><p>Red flags detected in asymptomatic carriers according to follow-up frequency.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">&#x0003e;1 Visit per Year</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">&#x02264;1 Visit per Year</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">%</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>CNS alterations</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.342</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ophthalmic alterations</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.555</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Cardiac alterations</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.680</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Carpal tunnel syndrome</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.455</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Gastrointestinal alterations</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">16.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.267</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Autonomic neuropathy</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">22.7</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">10.7</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.276</td></tr></tbody></table><table-wrap-foot><fn><p>CNS: central nervous system.</p></fn></table-wrap-foot></table-wrap></floats-group></article>